LGM | Jotup

Ikigai Labs’ Generative AI Platform Now Available in AWS Marketplace

Retrieved on:

Tuesday, April 9, 2024

AWS customers will now have seamless access to a powerful platform driving predictive and actionable insights in their trusted AWS Marketplace .

Key Points:

AWS customers will now have seamless access to a powerful platform driving predictive and actionable insights in their trusted AWS Marketplace .
The Ikigai platform provides AWS customers with the ability to streamline the purchase and management of Ikigai Labs’ AI platform and solutions in their AWS Marketplace account.
Ikigai Labs’ availability through AWS Marketplace now empowers enterprises to transform their valuable enterprise data into business outcomes quickly – all through out-of-the-box, API toolkits and low-code/no-code AI models trained on their own data.”
Ikigai Labs is now generally available in AWS Marketplace.
For more information on Ikigai Labs and its generative AI platform, please visit https://www.ikigailabs.io .

Ikigai Labs’ Generative AI Platform Now Available in the Microsoft Azure Marketplace

Retrieved on:

Wednesday, April 3, 2024

Software, Technology, Artificial Intelligence, Data Management, Microsoft, Forecasting, Learning, Environment, LGM, Acquisition, Video game

Ikigai Labs , a company that unlocks the power of generative AI for tabular and time series data, today announced the availability of its AI platform in the Microsoft Azure Marketplace , an online store providing applications and services for use on Azure.

Key Points:

Ikigai Labs , a company that unlocks the power of generative AI for tabular and time series data, today announced the availability of its AI platform in the Microsoft Azure Marketplace , an online store providing applications and services for use on Azure.
Ikigai Labs customers can now take advantage of the productive and trusted Azure cloud platform with streamlined deployment and management.
Ikigai’s AI application platform is built on its patented Large Graphical Models (LGM) - aiMatch , aiCast and aiPlan - to deliver powerful time series AI applications for data reconciliation, forecasting and planning.
The Azure Marketplace helps connect companies seeking innovative, cloud-based solutions with partners who have developed solutions that are ready to use.

LGM Pharma Unveils Enhanced Analytical Testing Services and Expands CDMO Portfolio with Additional Suppository Manufacturing Capabilities

Retrieved on:

Wednesday, March 13, 2024

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced a significant enhancement of its capabilities: a 50% expansion and an investment exceeding $2 million in its standalone offering for Analytical Testing Services (ATS) alongside the introduction of new suppository manufacturing capabilities to its contract development and manufacturing (CDMO) portfolio.

Key Points:

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced a significant enhancement of its capabilities: a 50% expansion and an investment exceeding $2 million in its standalone offering for Analytical Testing Services (ATS) alongside the introduction of new suppository manufacturing capabilities to its contract development and manufacturing (CDMO) portfolio.
With a broad array of analytical testing capabilities for small-molecule drug substances and drug products, LGM Pharma can meet the demands of large and small clients, from established pharmaceutical companies to start-ups.
In addition to analytical testing, the company provides comprehensive method development and validation services, as well as stability testing, including real-time and accelerated stability studies.
“As patient needs become increasingly diversified, the pharmaceutical industry needs CDMO partners that can provide specialized capabilities,” said Ian Gibson, Executive Vice President of Operations at LGM Pharma.

Ikigai Labs AI Platform Now Available on SAP® Store

Retrieved on:

Wednesday, February 21, 2024

Professional Services, Data Management, Technology, Data Analytics, Software, Artificial Intelligence, Forecasting, SAP, MIT, Learning, API, LGM, Research

Ikigai Labs , today announced that its AI platform is now available on SAP® Store , the online marketplace for SAP and partner offerings.

Key Points:

Ikigai Labs , today announced that its AI platform is now available on SAP® Store , the online marketplace for SAP and partner offerings.
Leveraging its patented Large Graphical Model (LGM) technology, the Ikigai platform integrates with SAP to deliver AI-enabled data reconciliation, time series forecasting and scenario planning across a broad range of industry and horizontal use cases.
“In today's rapidly evolving business climate, we need to equip decision makers with insights that are informed by their own data as well as external factors,” said Kamal Ahluwalia, president of Ikigai Labs.
The Ikigai platform also enables eXpert-in-the-loop (Xitl) for model reinforcement learning and refinement at scale.

Ikigai to Showcase Unique Generative AI Solution for Retail Demand Forecasting at NRF 2024 Innovation Lab

Retrieved on:

Sunday, January 14, 2024

During the show, Ikigai Labs will showcase retail applications of its generative AI platform for tabular data.

Key Points:

During the show, Ikigai Labs will showcase retail applications of its generative AI platform for tabular data.
Ikigai Labs’ gen AI approach to time series and tabular data rewrites the way companies approach data reconciliation, demand forecasting and planning.
Visitors to the Ikigai booth #8005 will experience Ikigai’s capabilities first-hand, learn about the company’s generative AI platform, and its aiMatch, aiCast and aiPlan models that power industry solutions such as demand forecasting for retail .
To learn more about the Ikigai Labs demand forecasting solution, visit Ikigai's retail page .

EG Acquisition Corp. Announces Intention to Transfer Listing from The New York Stock Exchange and Planned Listing by flyExclusive on NYSE American LLC Upon Consummation of its Pending Business Combination

Retrieved on:

Saturday, December 16, 2023

Professional Services, Air, Transport, Finance, LGM, NYSE, Business analyst, Security (finance), Special-purpose acquisition company, NYSE American, Person, Communication, Name

The Company’s Class A common stock and public warrants will continue to trade on the NYSE under the symbols “EGGF” and “EGGFW,” respectively, until and subject to the consummation of the Business Combination.

Key Points:

The Company’s Class A common stock and public warrants will continue to trade on the NYSE under the symbols “EGGF” and “EGGFW,” respectively, until and subject to the consummation of the Business Combination.
Following and subject to the consummation of the Business Combination, flyExclusive’s Class A common stock and public warrants would trade on the NYSE American under the symbols “FLYX” and “FLYXW,” respectively.
This communication does not contain all the information that should be considered concerning the Business Combination.
It is not intended to provide the basis for any investment decision or any other decision in respect to the proposed Business Combination.

Noodle.ai Announces Patent-Pending Technology for Generative Supply Chain Planning

Retrieved on:

Tuesday, September 26, 2023

Intelligence, GNN, General Planning Commission (France), LGM, Patent, Nature, SAN, Generative, GPP, Data science, 3D printing, Renewable energy, Online shopping

SAN FRANCISCO, Sept. 26, 2023 /PRNewswire/ -- Last week, Noodle.ai, the leader in Supply Chain A.I., had its patent application filed for the core GPP technology underlying its new Generative Supply Chain Planning.

Key Points:

SAN FRANCISCO, Sept. 26, 2023 /PRNewswire/ -- Last week, Noodle.ai, the leader in Supply Chain A.I., had its patent application filed for the core GPP technology underlying its new Generative Supply Chain Planning.
The technology, which is probabilistic in nature, has the ability to drive dramatic increases in supply chain profitability and dramatic decreases in supply chain waste.
Noodle.ai had its patent application filed for their GPP technology underlying its new Generative Supply Chain Planning.
"We are convinced the GPP technology will mark a key milestone in the transition to a future of Generative Planning."

LGM Pharma Reports Strong Revenues in First Year of CDMO Operations Along With Continued Growth in Its API Sourcing Business

Retrieved on:

Wednesday, March 15, 2023

Demand in 2022 also remained strong for LGM Pharma’s established API Services division, with over 300 unique APIs delivered and 1700+ imports handled for clients.

Key Points:

Demand in 2022 also remained strong for LGM Pharma’s established API Services division, with over 300 unique APIs delivered and 1700+ imports handled for clients.
The CDMO division works with multiple dosage forms including oral solid dosages, oral disintegrating tablets, powders, liquids, suspensions, semi-solids and suppositories.
“The strong start posted by our CDMO business reflects our company-wide commitment to supporting customer needs with quality-assured, customer-centric strategies.
By understanding the full life cycle of a product upfront, LGM can address their API sourcing needs in a sustainable and scalable way.

Polen Capital Expands Emerging Markets Capabilities, Launches Hong Kong Office

Retrieved on:

Wednesday, March 1, 2023

Professional Services, Finance, Research, Growth, Capital, Emerging market, LGM, Philosophy, Columbia Threadneedle Investments

Polen Capital, a global asset manager, today announced the expansion of its Emerging Markets franchise, hiring LGM’s core Emerging Markets and China Equity investment teams, effective today.

Key Points:

Polen Capital, a global asset manager, today announced the expansion of its Emerging Markets franchise, hiring LGM’s core Emerging Markets and China Equity investment teams, effective today.
The agreement sees an additional six investment professionals joining Polen Capital, bringing the expanded franchise to now include six strategies and 10 investment professionals, based in London and Polen’s newly launched Hong Kong office.
Polen will onboard and rebrand the team’s core emerging markets strategies and products including Emerging Markets Growth, China Growth and Emerging Markets Small Company Growth.
The team brings deep experience and a long track record building concentrated, quality growth portfolios in emerging markets, which aligns well with Polen’s focused investment philosophy,” said Damian Bird, Head of the Polen Emerging Markets Growth team.

LGM Pharma’s Unique Mix of API Sourcing and CDMO Services Is Fueling Robust Growth

Retrieved on:

Tuesday, May 17, 2022

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product life cycle, today reported that its unique mix of active pharmaceutical ingredient (API) sourcing and contract development and manufacturing (CDMO) services is helping to drive robust growth.

Key Points:

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product life cycle, today reported that its unique mix of active pharmaceutical ingredient (API) sourcing and contract development and manufacturing (CDMO) services is helping to drive robust growth.
Leveraging synergies and accelerating growth were key drivers of LGM Pharmas 2020 acquisition of a formulation development and finished dose CDMO to complement the companys global API sourcing business.
Our growing customer base understands the value of our integrated drug product CDMO and industry-leading API sourcing capabilities, said Dr. Prasad Raje, Chief Executive Officer of LGM Pharma.
To learn more about LGM Pharmas unique integrated suite of API sourcing and drug product CDMO services, visit LGM Pharmas Booth (#1615) at CPhI North America , May 17-19, 2022, Philadelphia, PA.
LGM Pharma is a leading contract development and manufacturing organization (CDMO) providing comprehensive active pharmaceutical ingredient (API) sourcing and drug product CDMO solutions to the pharmaceutical, biotechnology, and compounding pharmacy industries.